Product Description
Benzbromarone is a nonpurine xanthine oxidase inhibitor used for the treatment of gout, but never approved for use in the United States because of concerns over reports of acute liver injury and deaths with its use. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Benzbromarone)
Mechanisms of Action: URAT1 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Brazil | Chile | China | Dominican Republic | Egypt | Hong Kong | Malaysia | Netherlands | Pakistan | Portugal | Singapore | Slovenia | Spain | Taiwan | Thailand | United Kingdom
Approved Indications: None
Company: Jiangsu Hengrui Medicine Co
Company Location: Asia Pacific
Company Founding Year: 1970
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Gout
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05504083 |
D0120-206 | P2 |
Completed |
Gout |
2024-05-18 |
2024-10-16 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
CTR20221594 |
CTR20221594 | P2 |
Completed |
Unknown |
2024-11-08 |
2025-04-29 |
Primary Completion Date|Start Date|Study Completion Date |